SEC Form 4 · accession 0001209191-18-030727
Atara Biotherapeutics, Inc. · ATRA
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Derrell Porter
Officer — SVP, Head of Global Commercial
Period of report
May 15, 2018
Accepted (ET)
May 16, 2018 · 8:41 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001604464
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | May 15, 2018 | M | 16,334 | $14.30 | A | 28,834 | D | |
| Common StockF2 | May 15, 2018 | S | 16,334 | $45.02 | D | 12,500 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Option (Right to Buy)F3 | $14.30 | May 15, 2018 | M | 16,334 | D | — | May 10, 2024 | Common Stock | 16,334 | 113,666 | D |
Explanation of responses
- F1Transaction pursuant to Rule 10b5-1 Plan adopted March 9, 2018.
- F2The price in Column 4 is a weighted average sale price. The prices actually received ranged from $45.00 to $45.05. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range
- F325% of the shares subject to the option vest and become exercisable on May 10, 2018 and 1/48th of the shares subject to the stock option vest and become exercisable each full month thereafter.